ERBB2 and breast carcinoma: Furthermore, inline with our original finding that the CD47/SIRPα pathway also potently inhibits Fcγ receptor-mediated phagocytosis of IgG-opsonized host cells [139, 145, 146, 150], it has been shown that antibody-mediated blocking of CD47/SIRPα signaling promotes phagocytosis of non-Hodgkin lymphoma cells treated with rituximab [176] and antibody-dependent cellular cytotoxicity (ADCC) against Her2/Neu-positive breast cancer cells treated with traztusumab [177].